Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients
- PMID: 17287080
- DOI: 10.1016/j.neulet.2006.09.014
Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients
Abstract
Serotonin transporter (5-HTT) is a key component of the serotonergic neurotransmitter system. Few studies have focused on polymorphisms of the serotonin transporter and antipsychotic response and, in particular, there have so far been no published studies on the association between the serotonin transporter and response to risperidone. This study examined the relationship between two polymorphisms of the serotonin transporter and the efficacy of risperidone treatment in 129 patients with schizophrenia. Our results revealed that patients with l allele of HTTRLP showed a greater improvement than those without l allele on the overall brief psychiatric rating scale (BPRS) (P=0.025). But no such relationship was found for the HTTVNTR. In haplotype analysis, the frequency of L-12 haplotype showed a significant difference between the responder group and the non-responder group (P=0.005). Our study has, for the first time, produced evidence that the potential for therapy in patients with schizophrenia is related to the HTTRLP polymorphism in the HTT gene and haplotype L-12 may help to predict risperidone treatment efficiency.
Similar articles
-
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1562-6. doi: 10.1016/j.pnpbp.2008.05.022. Epub 2008 Jun 24. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18573584
-
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis.Psychiatry Res. 2010 Feb 28;175(3):189-94. doi: 10.1016/j.psychres.2008.12.011. Psychiatry Res. 2010. PMID: 20031235
-
Variation of the serotonin transporter gene SLC6A4 in the susceptibility to migraine with aura.Neurology. 2006 Nov 14;67(9):1707-9. doi: 10.1212/01.wnl.0000242883.96822.93. Neurology. 2006. PMID: 17101915
-
[Receptor polymorphism and response to treatment in schizophrenia].Orv Hetil. 2002 Sep 1;143(35):2027-33. Orv Hetil. 2002. PMID: 12387196 Review. Hungarian.
-
The serotonin pathway in pulmonary hypertension.Arch Mal Coeur Vaiss. 2006 Jun;99(6):621-5. Arch Mal Coeur Vaiss. 2006. PMID: 16878724 Review.
Cited by
-
Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Front Pharmacol. 2022 Oct 12;13:1005702. doi: 10.3389/fphar.2022.1005702. eCollection 2022. Front Pharmacol. 2022. PMID: 36313375 Free PMC article. Review.
-
Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.Methods Mol Biol. 2022;2547:389-425. doi: 10.1007/978-1-0716-2573-6_14. Methods Mol Biol. 2022. PMID: 36068471
-
Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behav Sci (Basel). 2021 Jun 30;11(7):97. doi: 10.3390/bs11070097. Behav Sci (Basel). 2021. PMID: 34209185 Free PMC article. Review.
-
Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates.Front Pharmacol. 2019 Apr 16;10:402. doi: 10.3389/fphar.2019.00402. eCollection 2019. Front Pharmacol. 2019. PMID: 31040787 Free PMC article. Review.
-
Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.J Neuroinflammation. 2017 Sep 4;14(1):179. doi: 10.1186/s12974-017-0938-y. J Neuroinflammation. 2017. PMID: 28870209 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
